MCID: HMG002
MIFTS: 48

Hemoglobinuria malady

Categories: Immune diseases, Blood diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria and paroxysmal cold hemoglobinuria, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Cyclophosphamide and Cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotype is hematopoietic system.

Wikipedia : 71 In medicine, hemoglobinuria or haemoglobinuria is a condition in which the oxygen transport protein... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 12.4
2 paroxysmal cold hemoglobinuria 12.3
3 paroxysmal nocturnal hemoglobinuria, somatic 12.2
4 paroxysmal nocturnal hemoglobinuria 2 12.1
5 blackwater fever 11.1
6 warm antibody hemolytic anemia 10.8
7 aplastic anemia 10.3
8 thrombosis 10.3
9 mental retardation, x-linked, snyder-robinson type 10.2 CD55 CD59 PIGA
10 budd-chiari syndrome 10.1
11 periventricular heterotopia with microcephaly 10.1 CD55 CD59 PIGT
12 malignant acth producing neoplasm of pituitary gland 10.1 C3 C5
13 leukemia 10.1
14 acro coxo mesomelic dysplasia 10.1 C3 HP
15 lung combined large cell neuroendocrine carcinoma 10.1 CD55 CD59 HP
16 muscular dystrophy limb girdle type 2a, erb type 10.0 CD55 CD59 PIGA PIGT
17 desmoplastic small round cell tumor 10.0 C3 C5
18 myelodysplastic syndrome 10.0
19 hemoglobinemia 10.0
20 hepatitis b 10.0 CD55 CD59 HP PIGA
21 cerebritis 10.0
22 thrombocytopenia 10.0
23 hemolytic anemia 9.9
24 macular degeneration, age-related, 13 9.9 C3 CR1
25 hematopoietic stem cell transplantation 9.9
26 purpura 9.9
27 hepatitis 9.8
28 lymphoma 9.8
29 retinitis 9.8
30 heparin-induced thrombocytopenia 9.8
31 geniculate ganglionitis 9.8 CD55 CR1 HP MB
32 hemosiderosis 9.8
33 multiple myeloma 9.7
34 myelofibrosis 9.7
35 neutropenia 9.7
36 pancytopenia 9.7
37 autoimmune hemolytic anemia 9.7
38 fasciitis 9.7
39 inherited bone marrow failure syndromes 9.7
40 myocardial infarction 9.6
41 systemic lupus erythematosus 9.6
42 hepatocellular carcinoma 9.6
43 hodgkin lymphoma 9.6
44 eosinophilic fasciitis 9.6
45 acute leukemia 9.6
46 chronic lymphocytic leukemia 9.6
47 retinal vein occlusion 9.6
48 lymphoblastic leukemia 9.6
49 fanconi syndrome 9.6
50 hemolytic-uremic syndrome 9.6

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

MGI Mouse Phenotypes related to Hemoglobinuria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 FCGR3B HP MB PIGA PLAUR C3

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Fludarabine Approved Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
5
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
6
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
7 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antilymphocyte Serum Phase 3,Phase 2
9 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
11 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12
Iodine Phase 3 7553-56-2 807
13 Antibodies Phase 3,Phase 2
14 Immunoglobulins Phase 3,Phase 2
15 Muromonab-CD3 Phase 3,Phase 2
16 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
18 Complement Inactivating Agents Phase 3,Phase 1,Phase 2
19 Complement System Proteins Phase 3,Phase 2,Phase 1
20
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0
21
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
22
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
23
Lenograstim Approved Phase 2 135968-09-1
24
Basiliximab Approved, Investigational Phase 2 152923-56-3, 179045-86-4
25
Busulfan Approved, Investigational Phase 2,Early Phase 1 55-98-1 2478
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Vidarabine Approved Phase 1, Phase 2, Early Phase 1 24356-66-9 32326 21704
29
Mechlorethamine Approved Phase 2 51-75-2 4033
30
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
32
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
33
Mesna Approved Phase 2 3375-50-6 598
34
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
35
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
36
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
37
Acetaminophen Approved Phase 2 103-90-2 1983
38
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
39
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
40
Promethazine Approved Phase 2 60-87-7 4927
41
Nandrolone Approved, Experimental, Illicit Phase 1, Phase 2 434-22-0, 62-90-8 9904 229455
42
Nandrolone decanoate Approved, Illicit Phase 1, Phase 2 360-70-3 9677
43
Everolimus Approved Phase 2 159351-69-6 6442177
44
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
47 tannic acid Approved, Nutraceutical Phase 2
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
50
decanoic acid Experimental Phase 1, Phase 2 334-48-5 2969

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4
2 The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Approved for marketing NCT00438789 Phase 3
3 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00098280 Phase 3
4 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00130000 Phase 3
5 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00122317 Phase 3
6 Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT00112983 Phase 3
7 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT00122330 Phase 3
8 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed NCT00122304 Phase 3
9 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
10 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
11 Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT Completed NCT00774527 Phase 3
12 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT02946463 Phase 3
13 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Enrolling by invitation NCT02393508 Phase 3
14 ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Not yet recruiting NCT03056040 Phase 3
15 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2
16 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2
17 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure Unknown status NCT00895739 Phase 2
18 E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01194804 Phase 2
19 C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01192399 Phase 2
20 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Completed NCT00065260 Phase 2
21 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2
22 Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Completed NCT00731328 Phase 2
23 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2
24 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
25 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2
26 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2
27 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2
28 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2
29 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2
30 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases Completed NCT02277639 Phase 2
31 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
32 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Recruiting NCT02591862 Phase 2
33 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT03157635 Phase 1, Phase 2
34 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03053102 Phase 2
35 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT02534909 Phase 2
36 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Recruiting NCT03030183 Phase 2
37 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Recruiting NCT03078582 Phase 2
38 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
39 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Recruiting NCT00003838 Phase 2
40 Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases Recruiting NCT02349906 Phase 2
41 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Recruiting NCT02224872 Phase 2
42 Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2
43 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2
44 Nandrolone Decanoate in the Treatment of Telomeropathies Recruiting NCT02055456 Phase 1, Phase 2
45 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2
46 Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Recruiting NCT01597219 Phase 2
47 An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Active, not recruiting NCT02598583 Phase 1, Phase 2
48 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Active, not recruiting NCT01642979 Phase 2
49 A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Active, not recruiting NCT02605993 Phase 2
50 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Active, not recruiting NCT01760096 Phase 2

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

id Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

39
Bone, Bone Marrow, Kidney, T Cells, Testes, Neutrophil, Monocytes

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 823)
id Title Authors Year
1
Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. ( 28528998 )
2017
2
Fluorescent Aerolysin (FLAER)-based paroxysmal nocturnal hemoglobinuria (PNH) screening: a single center experience from India. ( 28432724 )
2017
3
Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094-2101. ( 28408428 )
2017
4
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. ( 28124080 )
2017
5
Paroxysmal Nocturnal Hemoglobinuria in the Differential Diagnosis of Thrombocytopenia. ( 28435653 )
2017
6
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. ( 27837250 )
2017
7
Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. ( 28452421 )
2017
8
A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. ( 28380398 )
2017
9
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. ( 28332730 )
2017
10
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
11
Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. ( 28437723 )
2017
12
Paroxysmal Nocturnal Hemoglobinuria in a Case of Chronic Anemia. ( 28527178 )
2017
13
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. ( 28246555 )
2017
14
Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. ( 28124384 )
2017
15
Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. ( 27807852 )
2017
16
Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. ( 28447244 )
2017
17
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report. ( 28328837 )
2017
18
Role of kidney MRI to monitoring clearance of hemosiderin deposits in paroxysmal nocturnal hemoglobinuria. ( 28434706 )
2017
19
Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria. ( 26911378 )
2016
20
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. ( 26830487 )
2016
21
Pathogenesis of paroxysmal nocturnal hemoglobinuria. ( 27725586 )
2016
22
Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed. ( 27812245 )
2016
23
Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. ( 27913482 )
2016
24
Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. ( 26857155 )
2016
25
Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. ( 27884975 )
2016
26
An unusual association of paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, and diffuse large B-cell non-Hodgkin lymphoma in a Caucasian man. ( 27324258 )
2016
27
Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. ( 27307199 )
2016
28
Cerebral venous thrombosis presenting with intracerebral hemorrhage in a patient with paroxysmal nocturnal hemoglobinuria. ( 27076714 )
2016
29
Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. ( 27810992 )
2016
30
Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment. ( 27644115 )
2016
31
Dacie JV. Diagnosis and mechanism of hemolysis in chronic hemolytic anemia with nocturnal hemoglobinuria. ( 26823505 )
2016
32
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. ( 26792457 )
2016
33
Recovery with a regular dose of antibiotics from bacillary hemoglobinuria in a Holstein cow. ( 27498996 )
2016
34
Long-term follow-up of non-syphilitic paroxysmal cold hemoglobinuria in an adult. ( 27259986 )
2016
35
Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome: a case report. ( 26744238 )
2016
36
Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria. ( 27759825 )
2016
37
Successful Treatment of Ascites using a Denver(Ar) Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome. ( 27746432 )
2016
38
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. ( 27536121 )
2016
39
Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. ( 26852134 )
2016
40
Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis. ( 27757214 )
2016
41
Paroxysmal cold hemoglobinuria in a child with respiratory syncytial virus: an underrecognized cause of hemolytic anemia. ( 27162111 )
2016
42
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. ( 26839475 )
2016
43
The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria. ( 27780113 )
2016
44
Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. ( 27873177 )
2016
45
"Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications". ( 27598686 )
2016
46
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. ( 27464489 )
2016
47
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. ( 26690023 )
2016
48
Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( 27445073 )
2016
49
Zonal cutaneous ulceration and necrosis of the lower abdomen due to cutaneous thrombosis associated with paroxysmal nocturnal hemoglobinuria. ( 27790741 )
2016
50
Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? ( 26990688 )
2016

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 C3 C5 CD14 CD55 CD58 CD59
2
Show member pathways
11.98 C3 CR1 FCGR3B
3 11.96 C3 CD14 CR1 FCGR3B
4 11.88 C3 CD14 FCGR3B
5
Show member pathways
11.82 C3 C5 CD55 CD59 CR1
6
Show member pathways
11.68 C3 C5 CD55 CD59 CR1
7
Show member pathways
11.66 FCGR3B PIGA PIGT PLAUR
8 11.62 C3 CR1 FCGR3B
9 11.61 CD14 CD55 CD59 CR1
10 11.55 C3 C5 CD14
11 11.38 C3 C5 FCGR3B
12
Show member pathways
11.38 C3 C5 CD55 CD59 CR1
13 11.35 C3 CD14 CR1
14 11.24 C3 C5 CD55 CD59 CR1 PLAUR
15
Show member pathways
11.16 PIGA PIGT

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 C3 C5 CD14 CD55 CD59 FCGR3B
2 extracellular exosome GO:0070062 9.9 C3 C5 CD14 CD55 CD58 CD59
3 cell surface GO:0009986 9.73 CD14 CD55 CD58 CD59 CR1 PLAUR
4 ficolin-1-rich granule membrane GO:0101003 9.5 CD55 CD58 CR1
5 anchored component of external side of plasma membrane GO:0031362 9.4 CD14 CD59
6 secretory granule membrane GO:0030667 9.35 CD14 CD55 CD58 CR1 FCGR3B
7 anchored component of membrane GO:0031225 9.17 CD14 CD55 CD58 CD59 FCGR3B PLAUR

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.76 C3 C5 CD14 SEMA7A
2 innate immune response GO:0045087 9.72 C3 C5 CD14 CD55 CR1
3 positive regulation of protein phosphorylation GO:0001934 9.65 C3 PLAUR SEMA7A
4 immune system process GO:0002376 9.65 C3 C5 CD14 CD55 CR1
5 GPI anchor biosynthetic process GO:0006506 9.51 PIGA PIGT
6 positive regulation of vascular endothelial growth factor production GO:0010575 9.49 C3 C5
7 complement activation, classical pathway GO:0006958 9.46 C3 C5 CD55 CR1
8 positive regulation of interleukin-8 secretion GO:2000484 9.43 CD14 CD58
9 complement activation, alternative pathway GO:0006957 9.4 C3 C5
10 attachment of GPI anchor to protein GO:0016255 9.37 PIGT PLAUR
11 regulation of complement activation GO:0030449 9.35 C3 C5 CD55 CD59 CR1
12 neutrophil degranulation GO:0043312 9.28 C3 CD14 CD55 CD58 CD59 CR1

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.96 C3 C5
2 receptor binding GO:0005102 8.92 C3 C5 CD58 PLAUR

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....